Xiaoxian (Bill) Li
ORCID: 0000-0002-0995-1721
· 1 paper in corpus
2022
Abstract The new HER2-targeting antibody drug conjugate offers the opportunity to treat patients with HER2-low breast cancer. Distinguishing HER2 immunohistochemistry (IHC) scores of 0 and 1+, is critical but also challenging due to HER2 h…